▽panobinostat - PubMed - NCBI ●01/09 07:25 Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.Van Veggel M, Westerman E, Hamberg P. Van Veggel M, et al. Clin Pharmacokinet. 2018 Jan;57(1):21-29. doi: 10.1007/s40262-017-0565-x. Clin Pharmacokinet. 2018. PMID: 28667459 Review.The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins. Renal impairment does not influence the intrinsic ph
▽siltuximab - PubMed - NCBI ●01/09 07:23 Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC. van Rhee F, et al. Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112. Blood Adv. 2022. PMID: 35793409 Free PMC article. Clinical Trial.We performed post hoc analyses of the pha
▽AML - PubMed - NCBI ●01/09 06:37 2024 330646,077 resultsPage of 4,60846,077 resultsPage of 4,608of 4,608
▽Kyowa Hakko Kirin Co., Ltd. ●01/09 06:24 Integrated Report 2023We strive to contribute to the health and well-being of people aroundthe world by creating new value through the pursuit ofadvances in life sciences and technologies.See more
